2022 KNOW YOUR NETs Patient and Caregiver Virtual Conference Registration is open!

We are excited to announce that registration is now open for our 2022 KNOW YOUR NETs Patient and Caregiver Virtual Conference. You can view topics here and the final conference agenda is coming soon! Register below.

LUTATHERA UPDATE

On May 5, Novartis announced a temporary, voluntary suspension of production of Lutathera at its production sites in New Jersey and Italy. Novartis said it has taken this action out of an abundance of caution as it addresses potential quality issues identified in its manufacturing processes. As a result, the company is temporarily suspending delivery of Lutathera to PRRT providers in the United States and Canada. Novartis’ statement says a thorough review is underway and the company hopes to resume some supply within six weeks.

For more on what this may mean for patients with NETs, check out this webinar hosted by Josh Mailman, NETRF Board member and NorCal CarciNET president.

Have you listened to our latest NETWise Podcast?

Have you listened to our latest NETWise podcast? Episode 18 looks at high-grade NETs and NECs with experts from Memorial Sloan Kettering Cancer Institute, Fox Chase Cancer Center and the Mayo Clinic.

While most neuroendocrine tumors are low-grade and slow growing, there are some that are high-grade and very aggressive. These high-grade NETs are treated very differently. In the newest episode of NETWise, we turn the spotlight on high-grade NETs, talk with NET physicians about the treatment challenges, and hear from a patient and caregiver about dealing with the diagnosis. Listen here.

Test your knowledge!

After you've listened to the latest NETWise podcast, test your knowledge by taking the LACNETS post podcast quiz here.

NANETS/NETRF Research Funding Opportunity

NANETS Basic/Translational Science

Investigator supported by the NETRF

The North American Neuroendocrine Tumor Society (NANETS) is now accepting applications for its Basic Translational Science Investigator (BTSI) Award, which is funded by NETRF. The purpose of the grant is to encourage scientists at the end of their fellowship who have secured a faculty appointment or scientists beginning their faculty appointment to pursue research focused on neuroendocrine tumors. NETRF has supported the BTSI grant since 2016.

Applications are due on June 20, 2022. For eligibility criteria and instructions on how to apply, visit NANETS Grant Portal.

COMPOSE Study

The COMPOSE study, which is a randomized Phase 3 study with Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 (KI 67 index 15-55) Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) is open for recruitment in the United States. There are currently 3 active US sites—MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Washington University Alvin J. Siteman Cancer Center.

Information about the study inclusion and exclusion criteria can be found here or contact ITM at info-solucin@itm.ag

Thank you to everyone who donated to applaud the health care providers who help patients every day! We received 36 gifts, bringing our fundraising total to nearly $15,000.00 in honor of 34 dedicated health care providers! You can see all of those honored listed above.

Donations like these make a huge difference in our ability to continue to fund NET research. The research advancements and patient education programs that we fund at NETRF are possible through your generosity.

Thank you!!

"This was going to be our time, our next adventure..."

Seven years ago Mike and Leanne Carroll were packing up their life in the states to move to Germany for Mike's next big career move. Just eighteen months later they were back in the states facing Mike's pancreatic neuroendocrine cancer diagnosis.

Read their story here and why raising money for NETRF is so very important in Leanne's healing journey after losing her husband of 31 years.

What's Your Legacy?

NETRF has announced the launch of the NETRF Legacy Society which honors individuals who include NETRF in their estate plans.

Membership is extended to those who have made a provision in their will or estate plans for the Neuroendocrine Tumor Research Foundation. These future gifts will sustain ongoing NET research around the globe and provide hope for generations of NET patients and their families. Learn more here.

The NETRF team is truly grateful for the foresight and thoughtfulness of donors who include a provision for NETRF and NET research in their estate plans. These commitments will have a profound impact on NET research for generations to come and will inspire others to give through a legacy gift.

Special thanks to Advanced Accelerator Applications and Ipsen for sponsoring this May E-update.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

31 St. James Avenue, Suite 365
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.